Closer to home I'd suggest you read the announcement yesterday from Telix pharma (TLX), regarding their prostate cancer trial using rADC. This is the path Cheryl has identified going forward, question is how much catch up is there to be done? TLX already through phases 1 and 2 with data from 240 plus patients. What role for DEP in future?
SPL Price at posting:
11.5¢ Sentiment: None Disclosure: Not Held
